Are you aware that chronic cannabis use can lead to severe, recurring vomiting, sending users to the hospital? This is the reality for some, and it's a growing concern. Around 20,000 visitors are expected at the three-day event. This article delves into the emerging issue of cannabis hyperemesis syndrome (CHS), a condition increasingly recognized in medical settings. But here's where it gets controversial: patients often resist the diagnosis. Let's explore why.
Over the past decade, emergency rooms across the U.S. have witnessed a surge in patients seeking help for abdominal pain and intense vomiting, and this is frequently linked to chronic cannabis use. Until recently, doctors lacked a standardized way to document this condition, but now they have a diagnostic code for “cannabis hyperemesis syndrome,” a gastrointestinal disorder that begins within 24 hours of the most recent cannabis use and can last for several days. Those affected typically experience these symptoms three or four times annually.
The World Health Organisation is paving the way. From October 1st, 2025, the WHO will include a formal entry for CHS in its International Classification of Diseases manual (ICD-10). The U.S. Centers for Disease Control and Prevention (CDC) has adopted the new code, R11.16, into U.S. diagnostic systems. This code offers several benefits. Clinicians can now document the syndrome with a single, specific billing code, improving data reliability. This allows researchers to track cases more accurately and identify patterns that were previously difficult to discern. Medical researchers rely on data from clinicians, communities, and health records. The new code provides crucial hard evidence on adverse events related to cannabis, which physicians report as a growing problem.
But here's a surprising twist: Limited awareness contributes to delayed diagnosis. Many healthcare providers are still unfamiliar with CHS because it's a relatively new diagnosis. Even with an accurate diagnosis, some patients struggle to accept that cannabis is the source of their severe symptoms, especially since cannabis is widely known for easing nausea in other contexts. And this is the part most people miss: Why the syndrome affects some cannabis users but not others remains unclear. Is it the increased availability of cannabis, the higher THC potency of some products, or something else?
Treatment is also challenging. Standard anti-nausea medications often fail, sometimes forcing clinicians to use second and third-line options. Some individuals find limited relief through capsaicin cream, an over-the-counter analgesic, or hot showers. Several factors can slow recovery, including the intermittent nature of the syndrome and the potential for addiction.
What are your thoughts on this emerging issue? Do you think the increased availability of high-potency cannabis products plays a role? Share your opinions in the comments below!
